Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
· Idefirix® is among a few selected medicines to be granted ASMR 3 (Amélioration du service médical rendu) by the French Transparency Commission, which represents a level of clinical added benefit, and has also received SMR Important1 · The opinion by the Transparency Commission follows after Idefirix® was granted a funded Early Access Program by the French Haute Autorité de Santé (HAS) in February this year · Commercial launch activities for Idefirix® in Europe continue to progress Lund, Sweden, April 20, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in